Aprea Therapeutics (NASDAQ: APRE) investors approve reverse split range
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Aprea Therapeutics, Inc. reported results of its 2026 annual stockholder meeting. Of 12,382,776 common shares entitled to vote, 8,268,451 shares, or approximately 66.8%, were represented, establishing a quorum.
Stockholders elected three Class I directors—Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.—to serve until the 2029 annual meeting or until successors are elected and qualified. EisnerAmper LLP was ratified as independent registered public accounting firm for fiscal year 2026.
Stockholders approved an amendment to the certificate of incorporation authorizing the board to implement a reverse stock split at a ratio between one-for-three and one-for-eight, with the exact ratio and timing left to the board’s discretion. They also approved, on a non-binding basis, executive compensation and, by advisory vote, indicated a preference for annual say-on-pay votes. An adjournment proposal related to the reverse split was also approved.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 12,382,776 shares
Shares represented: 8,268,451 shares
Reverse split range: 1-for-3 to 1-for-8
+4 more
7 metrics
Shares entitled to vote
12,382,776 shares
Common stock entitled to vote at 2026 annual meeting
Shares represented
8,268,451 shares
Shares present in person or by proxy, about 66.8% participation
Reverse split range
1-for-3 to 1-for-8
Authorized board discretion for common stock reverse split
Reverse split approval votes for
8,038,052 votes
Votes for Proposal 3 authorizing reverse stock split range
Auditor ratification votes for
8,107,969 votes
Votes for ratifying EisnerAmper LLP for fiscal year 2026
Say-on-pay votes for
5,777,837 votes
Non-binding advisory approval of named executive officer compensation
Say-on-pay 1-year frequency votes
4,276,181 votes
Votes favoring annual advisory vote on executive compensation
Key Terms
reverse stock split, non-binding advisory vote, broker non-votes, quorum
4 terms
reverse stock split financial
"authorized the Board to effect a reverse stock split of the Common Stock at a ratio of not less than one-for-three and not more than one-for-eight"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
non-binding advisory vote financial
"stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers"
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
broker non-votes financial
"as well as abstentions and broker non-votes, if applicable, in respect of each such proposal"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
quorum financial
"8,268,451 shares, or approximately 66.8%, were represented at the Annual Meeting in person or by proxy, constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
FAQ
What did Aprea Therapeutics (APRE) stockholders approve at the 2026 annual meeting?
Stockholders approved director elections, auditor ratification, an amendment enabling a reverse stock split, non-binding executive compensation, say-on-pay frequency preferences, and an adjournment proposal related to the reverse split, covering governance and capital-structure flexibility items.
What reverse stock split range did Aprea Therapeutics (APRE) stockholders authorize?
Stockholders authorized the board to implement a reverse stock split of common stock at a ratio between one-for-three and one-for-eight, with fractional shares rounded up and timing and exact ratio determined at the board’s discretion under the approved amendment.
Which directors were elected at Aprea Therapeutics’ 2026 annual meeting?
Stockholders elected Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D., as Class I directors to serve until the 2029 annual meeting of stockholders, or until their respective successors are duly elected and qualified under the company’s classified board structure.
Did Aprea Therapeutics (APRE) stockholders approve executive compensation in 2026?
Yes. Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, providing say-on-pay support while leaving the actual compensation decisions with the board’s compensation committee and broader governance framework.
What say-on-pay vote frequency did Aprea Therapeutics (APRE) stockholders prefer?
In the advisory vote on say-on-pay frequency, stockholders most strongly supported holding such votes every one year, compared with lower support for two-year or three-year intervals, guiding how often future executive compensation advisory votes may be scheduled.